Related Experiment Videos

Adverse reactions to co-trimoxazole in hospitalized medical patients

Insights

Co-trimoxazole, a fixed-dose combination of trimethoprim-sulfamethoxazole, was used in 2.2% of hospitalized patients. Adverse effects, primarily skin rashes and gastrointestinal issues, occurred in 8% of recipients, with higher incidence in females.

Area of Science:

  • Pharmacovigilance
  • Internal Medicine
  • Infectious Diseases

Background:

  • Co-trimoxazole (trimethoprim-sulfamethoxazole) is a commonly prescribed antibiotic.
  • Understanding its adverse effect profile in hospitalized patients is crucial for safe prescribing.

Purpose of the Study:

  • To evaluate the incidence and nature of adverse effects associated with co-trimoxazole in a large cohort of hospitalized medical patients.

Main Methods:

  • A drug surveillance program monitored 29,524 hospitalized patients.
  • Data collection focused on patients receiving co-trimoxazole, documenting adverse events, onset, resolution, and patient demographics.

Main Results:

  • Co-trimoxazole was administered to 649 (2.2%) patients.
  • 8% of recipients experienced adverse effects, most commonly skin rashes (3.5%) and upper gastrointestinal upsets (3.4%).
  • Adverse effects were more frequent in female patients and typically resolved upon drug discontinuation.

Conclusions:

  • Co-trimoxazole is generally well-tolerated in hospitalized patients, with most adverse effects being mild and transient.
  • Female sex was identified as a risk factor for experiencing adverse effects.
  • No severe or life-threatening reactions were reported in this cohort.

Related Concept Videos